to have originated from the FDA's Office of Surveillance and Epidemiology, with a letter from Judy Staffa, PhD, RPh, leading the FDA's meeting materials. Staffa presided over the meeting. Sharon Hertz, MD, director of FDA's division of anesthesia, analgesia, and addiction products, was in attendance.